血必净注射液与奥曲肽联合治疗重症急性胰腺炎的效果研究  

Effect of Xuebijing Injection Combined with Octreotide in the Treatment of Severe Acute Pancreatitis

作　　者：胡称心 HU Chengxin(Department of Intensive Care Medicine,Nanping Second Hospital,Nanping,Fujian Province,354200 China)

机构地区：[1]南平市第二医院重症医学科,福建南平354200

出　　处：《中外医疗》2022年第35期168-171,180,共5页China & Foreign Medical Treatment

基　　金：南平市科技计划项目(N2021J046)。

摘　　要：目的 分析重症急性胰腺炎(severe acute pancreatitis,SAP)患者应用血必净注射液与奥曲肽联合治疗取得的效果。方法 随机选取2019年1月—2021年12月期间南平市第二医院收治的SAP患者60例为研究对象,采用随机数表法分为两组,即对照组(30例)与研究组(30例)。两组均行常规对症治疗,对照组应用奥曲肽,研究组此基础上联合应用血必净注射液。比较两组临床取得的总有效率、症状与体征缓解与住院时间、血尿淀粉酶指标、炎症因子指标,以及不良反应发生率。结果 研究组总有效率(93.33%)高于对照组(70.00%),差异有统计学意义(χ^(2)=5.455,P<0.05)。研究组腹痛缓解时间、退热时间、胃肠减压时间与住院时间均较对照组短,差异有统计学意义(P<0.05)。用药7 d时,研究组血淀粉酶(86.65±15.47)U/L、尿淀粉酶(225.65±20.56)U/L均较对照组(98.65±14.78)U/L、(286.47±34.47)U/L低,差异有统计学意义(t=3.072、8.300,P<0.05),C反应蛋白(CRP)与肿瘤坏死因子α(TNF-α)均较对照组低,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 SAP患者应用血必净注射液与奥曲肽联合治疗效果确切,能够有效抑制血尿淀粉酶与炎症因子,加快康复进程,安全性佳。Objective To analyze pancreatitis characterized by severe acute pancreatitis(SAP)in patients treated with Xuebijing injection combined with octreotide.Methods A total of 60 patients with SAP admitted to the Nanping Second Hospital from January 2019 to December 2021 were randomly selected as the research objects and divided into two groups by random number table method,namely the control group(30 cases)and the study group(30 cases).Both groups received conventional symptomatic treatment,the control group received octreotide,the study group combined with Xuebijing injection on this basis.The total effective rate,symptom and sign relief and length of hospital stay,serum amylase index,inflammatory factor index,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group(93.33%)was higher than that of the control group(70.00%),and the difference was statistically significant(χ^(2)=5.455,P<0.05).The time of abdominal pain relief,fever reduction,gastrointestinal decompression and hospital stay in the study group were shorter than those in the control group,and the differences were statistically significant(P<0.05).Blood amylase(86.65±15.47)U/L and urine amylase(225.65±20.56)U/L in the study group were lower than those in the control group(98.65±14.78)U/L and(286.47±34.47)U/L on day 7 of medication,and the difference was statistically significant(t=3.072,8.300,P<0.05),C-reactive protein(CRP)and tumor necrosis factorα(TNF-α)were lower than those in control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combined treatment effect of Xuecijing injection and octreotide in SAP patients is accurate,which can effectively inhibit hematural amylase and inflammatory factors,accelerate the process of rehabilitation,and has good safety.

关 键 词：血必净注射液 奥曲肽 重症急性胰腺炎 

分 类 号：R5[医药卫生—内科学]